Emerging therapeutic agents in the treatment of relapsed or refractory diffuse large B cell lymphoma

Authors

  • Anthea Peters, MD, FRCPC

DOI:

https://doi.org/10.58931/cht.2022.1110

Abstract

Diffuse large B cell lymphoma (DLBCL) is the most common type of aggressive non-Hodgkin lymphoma (NHL). The median age at diagnosis of DLBCL is 65, and about one-third of patients are older than age 75 at diagnosis. The standard of care for frontline treatment is chemoimmunotherapy, consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP). Approximately 60% of patients are cured with standard treatment, but it is inaccessible for up to 25% of patients due to advanced age and underlying comorbidities, including cardiac dysfunction. Several biologic factors confer risk of treatment failure, including activated B cell (ABC) cell of origin and double expressor phenotype (i.e. and overexpression of c-MYC and BCL2).

Author Biography

Anthea Peters, MD, FRCPC

Dr. Anthea Peters is a hematologist based at the Cross Cancer Institute in Edmonton, Alberta and an Associate Professor in the Department of Oncology at the University of Alberta. She completed her MD at the University of Saskatchewan, internal medicine residency training at the University of Alberta and hematology training as well as a lymphoma fellowship at the University of Calgary. Her clinical and research interests are centered around lymphoma and chronic lymphocytic leukemia (CLL), with a special interest in post-transplant lymphoproliferative disorders. She is currently the clinical lead for lymphoma and CLL for Northern Alberta.

References

Di M, Huntington SF, Olszewski AJ. Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients. Oncologist. 2021;26(2):120-32. DOI: https://doi.org/10.1002/onco.13610

Sehn LH, Salles G. Diffuse Large B-Cell Lymphoma. N Engl J Med. 2021;384(9):842-58. DOI: https://doi.org/10.1056/NEJMra2027612

Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-42. DOI: https://doi.org/10.1056/NEJMoa011795

Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A. 2008;105(36):13520-5. DOI: https://doi.org/10.1073/pnas.0804295105

Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937-47. DOI: https://doi.org/10.1056/NEJMoa012914

Leonard JP, Martin P, Roboz GJ. Practical Implications of the 2016 Revision of the World Health Organization Classification of Lymphoid and Myeloid Neoplasms and Acute Leukemia. J Clin Oncol. 2017;35(23):2708-15. DOI: https://doi.org/10.1200/JCO.2017.72.6745

Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3452-9. DOI: https://doi.org/10.1200/JCO.2011.41.0985

Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3460-7. DOI: https://doi.org/10.1200/JCO.2011.41.4342

Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014;32(31):3490-6. DOI: https://doi.org/10.1200/JCO.2013.53.9593

Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-8. DOI: https://doi.org/10.1182/blood-2017-03-769620

Zinzani PL, Rodgers T, Marino D, Frezzato M, Barbui AM, Castellino C, et al. RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma. Clin Cancer Res. 2021;27(22):6124-34. DOI: https://doi.org/10.1158/1078-0432.CCR-21-1471

Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. 2021.

Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019;380(1):45-56. DOI: https://doi.org/10.1056/NEJMoa1804980

Maddocks K. Novel targets in aggressive lymphoma. Hematology Am Soc Hematol Educ Program. 2020;2020(1):101-6. DOI: https://doi.org/10.1182/hematology.2020000093

Salles G, Duell J, Gonzalez Barca E, Tournilhac O, Jurczak W, Liberati AM, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21(7):978-88. DOI: https://doi.org/10.1016/S1470-2045(20)30225-4

Duell J, Maddocks KJ, Gonzalez-Barca E, Jurczak W, Liberati AM, De Vos S, et al. Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica. 2021;106(9):2417-26. DOI: https://doi.org/10.3324/haematol.2020.275958

Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020;38(2):155-65. DOI: https://doi.org/10.1200/JCO.19.00172

Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trneny M, Sharman JP, et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med. 2021.

Matasar MJ, Haioun C, Sancho J-M, Viardot A, Hirata J, Perretti T, et al. POLARGO: Randomized Phase III Study of Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020;38(15 Supplement):TPS8070. doi:10.1200/JCO.2020.38.15_suppl.TPS8070 DOI: https://doi.org/10.1200/JCO.2020.38.15_suppl.TPS8070

Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021;22(6):790-800. DOI: https://doi.org/10.1016/S1470-2045(21)00139-X

Jacobsen ED, Sharman JP, Oki Y, Advani RH, Winter JN, Bello CM, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015;125(9):1394-402. DOI: https://doi.org/10.1182/blood-2014-09-598763

Ward J, Berrien-Elliott MM, Gomez F, Luo J, Becker-Hapak M, Cashen AF, et al. Phase I/Dose Expansion Trial of Brentuximab vedotin/Lenalidomide in Relapsed or Refractory Diffuse Large B-cell Lymphoma. Blood. 2021. DOI: https://doi.org/10.1182/blood.2021011894

Bartlett NL, Yasenchak CA, Ashraf K, Harwin W, Sims R, Nowakowski GS. Brentuximab Vedotin in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ECHELON-3, Trial in Progress). J Clin Oncol. 2021;39(15 Suppl)TPS7571. doi:10.1200/JCO.2021.39.15_suppl.TPS7571 DOI: https://doi.org/10.1200/JCO.2021.39.15_suppl.TPS7571

Viardot A, Goebeler ME, Hess G, Neumann S, Pfreundschuh M, Adrian N, et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood. 2016;127(11):1410-6. DOI: https://doi.org/10.1182/blood-2015-06-651380

Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon SS, Yoon DH, et al. Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. J Clin Oncol. 2022 Feb 10;40(5):481-91. DOI: https://doi.org/10.1200/JCO.21.00931

Kalakonda N, Maerevoet M, Cavallo F, Follows G, Goy A, Vermaat JSP, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol. 2020;7(7):e511-e22. DOI: https://doi.org/10.1016/S2352-3026(20)30120-4

Lee ST, Pinto A, Yimer H, Stevens D, Knopinska Posluszny W, Shum MK, et al. A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL). Blood. 2021;138(Supplement 1):1420. DOI: https://doi.org/10.1182/blood-2021-150025

Goy A, Ramchandren R, Ghosh N, Munoz J, Morgan DS, Dang NH, et al. Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL. Blood. 2019;134(13):1024-36. DOI: https://doi.org/10.1182/blood.2018891598

Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, et al. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. J Clin Oncol. 2017;35(8):826-33. DOI: https://doi.org/10.1200/JCO.2016.70.4320

Burke JM, Fonseca G, Jurczak W, Melear J, Islas-Ohlmayer M, Reeves JA, et al. Efficacy and Safety of Umbralisib, Ublituximab (U2), and U2 Plus Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL). Blood. 2021;138(Supplement 1):527. DOI: https://doi.org/10.1182/blood-2021-151054

Morschhauser F, Flinn IW, Advani R, Sehn LH, Diefenbach C, Kolibaba K, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol. 2019;6(5):e254-e65. DOI: https://doi.org/10.1016/S2352-3026(19)30026-2

Czuczman MS, Trneny M, Davies A, Rule S, Linton KM, Wagner-Johnston N, et al. A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator’s Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Clin Cancer Res. 2017;23(15):4127-37. DOI: https://doi.org/10.1158/1078-0432.CCR-16-2818

Published

2022-03-01

How to Cite

1.
Peters A. Emerging therapeutic agents in the treatment of relapsed or refractory diffuse large B cell lymphoma. Can Hematol Today [Internet]. 2022 Mar. 1 [cited 2024 Mar. 29];1(1):43–47. Available from: https://canadianhematologytoday.com/article/view/1-1-6-peters

Issue

Section

Articles